Abbott launches whole-genome sequencing Oncodetect MRD test
Abbott announced the commercial availability of its next-generation Oncodetect MRD test, a personalized, tumor-informed, whole-genome sequencing test that tracks up to 5,000 patient-specific variants with a limit of detection below one part per million. The company said the test could be used for patients with solid tumors.
Primary source
Company press release (PR Newswire), October 26, 2026
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Machine-summarized from the source above; not independently reported. How we use automation